The cost of Cefiderocol IV can vary significantly based on factors such as insurance coverage, the specific healthcare provider, and the quantity purchased.
How much does a Cefiderocol IV treatment typically cost?
For individuals paying out-of-pocket, the cost of Cefiderocol IV can be substantial. A single vial may range from approximately $300 to over $600. Since a full course of treatment can involve multiple vials, the total expense for uninsured patients could reach several thousand dollars. For example, a typical treatment duration might require 10 to 15 vials, leading to a potential cost of $3,000 to $9,000 or more.
Can Cefiderocol IV be obtained at a lower price?
Patients may be able to reduce the cost of Cefiderocol IV through various avenues. Pharmaceutical manufacturers often provide patient assistance programs designed to lower out-of-pocket expenses for eligible individuals. Additionally, comparing prices across different pharmacies or hospitals can sometimes yield savings. Insurance plans, if applicable, will significantly impact the final cost, with copays and deductibles determining the patient's responsibility.
When does Cefiderocol's patent protection expire?
The patent landscape for Cefiderocol is complex and evolving. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can indicate the timeline for generic competition. Understanding patent expiry dates is crucial for predicting future price reductions and the potential availability of biosimilar or generic alternatives. Specific details regarding Cefiderocol's patent status and projected expiry can be found on resources like DrugPatentWatch.com [1].
What are the approved uses for Cefiderocol IV?
Cefiderocol is an intravenous antibiotic approved for treating complicated urinary tract infections (cUTI), including pyelonephritis, and complicated intra-abdominal infections (cIAI) in adult patients who have limited or no alternative treatment options. It is specifically indicated for infections caused by Gram-negative bacteria, including difficult-to-treat multidrug-resistant organisms [2].
How is Cefiderocol administered and for how long?
Cefiderocol is administered intravenously. The duration of treatment typically depends on the type and severity of the infection. For complicated urinary tract infections, treatment is generally for 7 days, while for complicated intra-abdominal infections, it is usually for 7 to 14 days [2].
What are the potential side effects of Cefiderocol IV?
Common side effects associated with Cefiderocol IV include diarrhea, nausea, vomiting, headache, and elevated liver enzymes. Serious adverse reactions can also occur, such as Clostridioides difficile-associated diarrhea. Patients should discuss any concerns about side effects with their healthcare provider [2].
How does Cefiderocol IV work to treat infections?
Cefiderocol is a siderophore cephalosporin. It utilizes a unique mechanism by mimicking iron to be transported into bacterial cells through the outer membrane's iron uptake systems. Once inside, it binds to penicillin-binding proteins (PBPs), inhibiting bacterial cell wall synthesis and leading to cell death. This mechanism is effective against many Gram-negative bacteria that have developed resistance to other antibiotics [3].
Are there any Cefiderocol IV alternatives available?
Given Cefiderocol's indication for infections with limited or no alternative treatment options, alternatives are often dictated by the specific pathogen and its resistance profile. Other classes of antibiotics may be considered, but Cefiderocol is typically reserved for cases where other treatments have failed or are not suitable. Healthcare providers will choose the most appropriate therapy based on susceptibility testing and clinical guidelines.
Who is the manufacturer of Cefiderocol IV?
Cefiderocol is manufactured by Shionogi Inc. [2].
What clinical trials have been conducted for Cefiderocol IV?
Clinical trials have demonstrated Cefiderocol's efficacy in treating complicated urinary tract infections and complicated intra-abdominal infections. Key studies, such as the CREDIBLE-CR and CURE trials, provided data supporting its approval for these indications, particularly in patients with Gram-negative bacterial infections resistant to other agents [2].
Sources:
[1] DrugPatentWatch.com
[2] Shionogi Inc.
[3] DrugBank